OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
The BioMAP Fibrosis Early Screening Service (REMyoF) is a high quantity screening format in the BioMAP fibrosis system REMyoF, comprised of renal proximal tubule epithelial cells and lung fibroblasts. This system is stimulated with profibrotic and proinflammatory factors to model the biology of renal fibrosis and inflammation associated with chronic kidney diseases and end-stage renal failure. Biomarker readouts capture impacts on translationally relevant matrix remodeling, tissue repair, wound healing, and inflammation related responses in the diseased kidney. This service allows for rapid testing of 18 compounds at 4 concentrations for antifibrotic development potential in a human fibrosis model.
Organism:
Human
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Testing Information
Test Sample Requirements:
For Small Molecules, 50 ul of 1000X stock solution in 100% DMSO per agent. For Biologics, 500 ul of 100X stock solution in PBS or water per agent.
Minimum Order Quantity:
72
Turnaround Time
Standard:
30 Business Days
Clinical Relevance
Therapeutic Area:
Fibrosis
Additional Information
Brand:
BioMAP
Testing Location:
USA - St Charles, MO
RELATED SOLUTIONS
BioMAP Systems ELECT Menu 2 (REMyoF)
Item: 89-0003-0040
BioMAP Combo ELECT Menu 2 (REMyoF)
Item: 89-0015-0040
BioMAP Fibrosis Panel
Item: 89-0016-0904
BioMAP Fibrosis Early Screening Service (SAEMyoF)
Item: 89-0049-0042
BioMAP Fibrosis Early Screening Service (MyoF)
Item: 89-0049-0011
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
